Breast cancer pt hopi in detail to be present in seminar

Reading File

Now I'll search the medical library comprehensively for breast cancer history of presenting illness content across multiple dimensions in parallel.

Finding Sources

Excellent — I have great sources. Now let me read the key textbook sections in parallel: Goldman-Cecil (clinical presentation, staging, management), Sabiston (risk factors, surgical management), and Robbins (pathology).

Reading File

Good. Now let me read the clinical presentation, staging, investigation, and management sections in parallel.

Reading File

Searching PubMed

"breast cancer" AND "clinical presentation" AND diagnosis

Now let me read the clinical presentation and staging/management sections from Robbins and Goldman-Cecil, plus investigation section from Sabiston:

Reading File

Now let me get the clinical presentation, investigations, and TNM staging sections:

Reading File

Finding Sources

Excellent. Let me now read the TNM staging and Harrison's diagnosis sections:

Reading File

I now have comprehensive data from multiple authoritative textbooks. Let me also grab the TNM staging table and the clinical presentation section from Robbins:

Reading File

I now have comprehensive data from all major textbooks. Let me update the todos and compile the full seminar write-up.Now I'll compile the full detailed seminar-ready History of Presenting Illness (HoPI) for Breast Cancer:

🎓 BREAST CANCER — DETAILED HISTORY OF PRESENTING ILLNESS (HoPI) for Seminar Presentation

1. EPIDEMIOLOGY & BACKGROUND

Breast cancer is the most common non-skin malignancy in women worldwide, with approximately 2.25 million new cases diagnosed annually globally and ~290,000 new cases per year in the United States, resulting in ~43,000 deaths annually. It accounts for 12.9% cumulative lifetime incidence in women. Incidence and mortality are declining in the U.S. and Western Europe due to reduced postmenopausal hormone therapy use, widespread mammographic screening, and adjuvant systemic therapy. It is predominantly a disease of women; males represent <1% of cases and tend to present at more advanced stages.

— Goldman-Cecil Medicine, p. 2080; Harrison's Principles, 22E

2. RISK FACTORS

A. Demographic & Lifestyle

Risk Factor	Detail
Age	Most critical risk factor; <2% in women <20 yrs; peaks in 8th decade; 75% diagnosed after age 50
Female sex	Predominantly female; male cases <1%
Obesity	Especially postmenopausal; linked to peripheral aromatization of androgens to estrogen
Alcohol	Dose-dependent increased risk
Physical inactivity	Established modifiable risk factor
Shift work (nighttime)	Associated with increased risk
High-fat, low-fiber diet	Contributory role
Smoking	Associated especially in premenopausal women

B. Hormonal Exposure

Risk Factor	Detail
Early menarche	Before age 11 — prolonged estrogen exposure
Late menopause	After age 55
Nulliparity	No full-term pregnancies
Late first pregnancy	First full-term pregnancy after age 30
Lack of breastfeeding	Protective effect lost
HRT (combined E+P)	Combined estrogen+progesterone significantly increases risk; estrogen alone does not
Oral contraceptives	Slightly increased risk with ongoing use

C. Genetic & Family History

Risk Factor	Detail
Family history	~20% of breast cancers; first-degree relative with premenopausal breast cancer significantly elevates risk
BRCA1/BRCA2 mutations	Autosomal dominant; 50–85% lifetime risk of breast cancer
Li-Fraumeni syndrome	Germline TP53 mutation
Cowden syndrome	PTEN gene mutation
PALB2, CHEK2, ATM mutations	Moderate-penetrance DNA repair gene mutations
5–8% of breast cancers	Occur in high-risk hereditary families

D. Histologic Risk Factors

Lesion	Relative Risk (RR)
Dense breasts on mammography	Elevated risk
Proliferative disease without atypia (sclerosing adenosis, papillomas)	RR 1.3–1.9
Atypical ductal/lobular hyperplasia	RR 3.7–4.2
Lobular carcinoma in situ (LCIS)	RR >7
Prior invasive breast cancer	Contralateral risk ~0.1–0.6%/year

E. Environmental

Ionizing radiation to the chest wall, particularly during adolescence (e.g., prior mantle radiotherapy for Hodgkin lymphoma)
No confirmed association with estrogenic pesticides or high-fat diet alone

— Sabiston Textbook of Surgery, Box 68.1; Goldman-Cecil Medicine, p. 2080–2081

3. PATHOLOGY & SUBTYPES

Normal Breast Architecture

The breast consists of 5–15 ductal-lobular segments. The terminal duct lobular unit (TDLU) is the basic structural and functional unit. Each TDLU has luminal epithelial cells (inner), myoepithelial cells (outer), and a basement membrane separating them from stroma.

Pre-malignant / In Situ Lesions

Feature	LCIS	DCIS
Age	Younger	Older
Palpable mass	No	Uncommon
Mammogram	Not detected	Microcalcifications / mass
E-cadherin	Negative	Positive
Usual finding	Incidental biopsy	Mammographic screen
Bilateral	Common (20–40%)	Less common
Risk of invasive cancer	25% in either breast (lifetime)	0.5%/yr at same site

Invasive Carcinoma Types

Invasive Ductal Carcinoma (IDC/NST) — most common (~75%); haphazard glands invading stroma
Invasive Lobular Carcinoma (ILC) — single-file "Indian-file" pattern; targetoid growth around ducts; E-cadherin negative
Tubular Carcinoma — well-differentiated tubules; excellent prognosis
Mucinous (Colloid) Carcinoma — tumor cells floating in mucin lakes; good prognosis
Medullary Carcinoma — large undifferentiated cells, lymphocytic infiltrate, syncytial growth; often BRCA1-associated
Paget Disease of Nipple — DCIS extending into nipple skin; presents as eczematous nipple change

Molecular Subtypes (Intrinsic)

Subtype	ER	PR	HER2	Frequency	Grade/Ki67
Luminal A	+	+	−	40–60%	Low grade, low Ki67
Luminal B	+	+/−	−/+	20–30%	Higher grade, high Ki67
HER2-enriched	−	−	+	10–20%	Variable
Basal-like / Triple-negative (TNBC)	−	−	−	10–20%	High grade, high Ki67; BRCA1-associated

— Robbins Pathologic Basis of Disease, p. 954–966; Sabiston Textbook of Surgery

4. CLINICAL PRESENTATION (HoPI Core)

A. Common Presenting Features

When taking a detailed HoPI for a breast cancer patient, the following features must be systematically elicited:

1. Breast Lump / Mass (Most Common Symptom)

Location: Which breast? Which quadrant? (Upper outer quadrant — most common site, ~50%; contains most breast tissue)
Onset: When first noticed? Gradual or sudden?
Duration: How long ago?
Size: Has it changed in size?
Character:
- Malignant features: Hard, irregular, non-tender, fixed to underlying tissue or overlying skin
- vs. Benign (fibroadenoma): rubbery, mobile, well-defined, non-tender
Progression: Enlarging? Stable?
Associated symptoms: Pain, skin changes, nipple discharge, axillary lumps

2. Skin Changes

Dimpling / Tethering: Due to involvement of Cooper's ligaments by tumor → peau d'orange (lymphedema of skin)
Peau d'orange ("orange peel" skin): Due to lymphatic obstruction; classic sign of Inflammatory Breast Cancer (IBC)
Skin ulceration or nodularity: Advanced T4 disease
Erythema/warmth: IBC may mimic mastitis — key to ask about onset, whether on antibiotics with no response
Nipple retraction/inversion: Traction from tumor or periductal fibrosis

3. Nipple Changes

Nipple discharge: Character matters —
- Bloody or serosanguineous → most concerning for malignancy (also papilloma)
- Milky → galactorrhea (exclude prolactinoma)
- Green/yellow → duct ectasia
Paget's disease: Unilateral eczematous/scaly change of nipple ± underlying mass; must be differentiated from eczema (bilateral, responds to steroids)
Nipple retraction/inversion

4. Pain

Breast cancer is usually painless — pain is NOT a typical early feature
~10–15% may have pain; more common with benign disease (cyclic mastalgia)
Bone pain (back, hip, shoulder) → suggests metastatic disease (most common site: bone)

5. Axillary / Nodal Disease

Palpable axillary lymph nodes: How many? Mobile or fixed? Matted?
N1: mobile, ipsilateral axillary nodes
N2: fixed/matted axillary nodes
N3: supraclavicular, infraclavicular, internal mammary nodes
Ask about: arm swelling (lymphedema), arm pain

6. Symptoms of Metastatic Disease

Always ask a SYSTEMS REVIEW for metastases:

System	Symptom	Significance
Bone	Back pain, hip/rib pain, pathological fracture	Most common metastatic site
Lung	Dyspnoea, cough, haemoptysis, pleural effusion	Second most common
Liver	RUQ pain, jaundice, nausea, anorexia, weight loss	Visceral metastasis
Brain	Headache, seizures, focal neurological deficits	CNS involvement
Skin	Nodular skin deposits	Cutaneous metastasis

7. Constitutional Symptoms

Weight loss (unintentional — >10% body weight in 6 months)
Fatigue
Anorexia
Night sweats
Fever (rare, may indicate paraneoplastic or IBC)

B. Special Scenarios to Ask About

Inflammatory Breast Cancer (IBC)

Rapid onset (<3 months) of: breast erythema, edema, peau d'orange, warmth, heaviness
May have no discrete mass
Classified as T4d — locally advanced
Often mistaken for mastitis; does NOT respond to antibiotics

Locally Advanced Breast Cancer

Large mass >5 cm (T3)
Skin involvement, ulceration, satellite nodules (T4)
Fixation to chest wall (T4a)
Fixed/matted axillary nodes (N2)
Supraclavicular nodes (N3)

5. PAST HISTORY & RELEVANT HISTORY

Elicit systematically:

Previous breast lumps / biopsies → atypical hyperplasia? LCIS? Previous cancer?
Previous breast cancer in either breast
Gynecological history:
- Age at menarche (early = risk)
- Number and age at pregnancies
- Breastfeeding history
- Menopausal status (age at menopause)
- HRT use (type, duration)
- Oral contraceptive use
Prior chest wall radiation (e.g., for Hodgkin lymphoma before age 30)

6. FAMILY HISTORY

Detailed, structured family history is critical:

First-degree relatives (mother, sister, daughter) with breast cancer, and their age at diagnosis
Ovarian cancer in family (BRCA1/2 syndrome)
Bilateral breast cancer in a relative
Male relative with breast cancer (BRCA2)
Pancreatic cancer, prostate cancer (BRCA2 extended families)
Li-Fraumeni syndrome features: sarcomas, brain tumors, adrenal tumors in young family members
Ethnic background: Ashkenazi Jewish heritage (higher BRCA1/2 founder mutations)

7. SOCIAL HISTORY

Alcohol use (dose-dependent risk)
Smoking
Body weight / BMI / obesity
Physical activity
Diet
Occupation (night shift work)
Marital status, psychological impact
Support system, insurance/financial concerns

8. DRUG HISTORY & ALLERGIES

Current and past oral contraceptive use
HRT (combined vs. estrogen-only)
Tamoxifen or aromatase inhibitors (chemoprevention in high-risk)
Any prior chemotherapy or immunosuppressants
Allergies to drugs or iodine (important for contrast imaging)

9. REVIEW OF SYSTEMS (for Seminar Completeness)

System	Ask About
General	Weight loss, fatigue, fever, night sweats
Breast	Mass, skin/nipple changes, discharge, pain
MSK	Bone pain, fractures, back pain
Respiratory	Dyspnoea, cough, chest pain
GI	Jaundice, RUQ pain, nausea, change in bowel habits
Neurological	Headache, visual changes, weakness, confusion
Lymphatic	Axillary/neck/supraclavicular lumps, arm swelling

10. INVESTIGATIONS

A. Imaging

Investigation	Purpose
Mammography	First-line screening and diagnostic; detects microcalcifications, masses, architectural distortion; reduces mortality by 20–25% in women ≥50
Ultrasound (US)	Characterizes palpable masses; distinguishes cystic vs. solid; guides biopsy; preferred in women <35
MRI Breast	Highest sensitivity; used for: BRCA carriers, dense breasts, extent of disease, response to neoadjuvant therapy; does not replace biopsy
Chest X-ray	Baseline, lung metastases, pleural effusion
CT chest/abdomen/pelvis	Staging for locally advanced/metastatic disease
Bone scan	Bone metastases, especially with bone pain or elevated ALP
PET-CT	Functional staging in selected high-risk patients

B. Pathological Diagnosis — Triple Assessment

The gold standard is the "Triple Assessment":

Clinical examination — history + physical exam
Radiological assessment — mammogram ± ultrasound
Pathological / cytological — core needle biopsy (CNB) or fine needle aspiration cytology (FNAC)

Core Needle Biopsy (CNB) is preferred over FNAC because it provides:

Histological architecture
Hormone receptor status (ER, PR)
HER2 expression / gene amplification (FISH)
Ki-67 proliferation index
Tumor grade (Nottingham/Elston-Ellis grading)

Lymph node biopsy: Image-guided FNA/core of suspicious axillary nodes

C. Biomarkers

Marker	Significance
ER (Estrogen Receptor)	Positive ≥1% staining; guides endocrine therapy
PR (Progesterone Receptor)	Confirmatory; prognostic
HER2	Over-expression or amplification; guides trastuzumab therapy
Ki-67	Proliferation index; distinguishes Luminal A from B
Triple Negative (ER−/PR−/HER2−)	TNBC; chemotherapy-based treatment
BRCA1/2 germline testing	For qualifying patients (young, FH, TNBC)

D. Laboratory

Full blood count (FBC) — anaemia, leucocytosis
Liver function tests (metastasis)
Serum calcium (hypercalcaemia of malignancy)
Alkaline phosphatase (bone/liver metastasis)
Tumour markers: CA 15-3, CEA — not diagnostic, used for monitoring metastatic disease

11. STAGING (AJCC 8th Edition — TNM Anatomic)

T — Primary Tumor

Stage	Criteria
Tis	DCIS or Paget disease without invasive carcinoma
T1	Invasive tumor ≤20 mm
T1mi	≤1 mm
T1a	>1 mm to ≤5 mm
T1b	>5 mm to ≤10 mm
T1c	>10 mm to ≤20 mm
T2	>20 mm to ≤50 mm
T3	>50 mm
T4a	Extension to chest wall
T4b	Skin involvement (ulceration, satellite nodules)
T4c	Both 4a and 4b
T4d	Inflammatory breast cancer

N — Regional Lymph Nodes (Pathologic)

Stage	Criteria
pN0	No regional LN metastases
pN1mi	Micrometastases (>0.2 mm but ≤2.0 mm)
pN1	1–3 positive axillary nodes / internal mammary (by SLN biopsy)
pN2	4–9 positive axillary nodes OR clinically detected internal mammary nodes
pN3	≥10 axillary nodes OR infraclavicular nodes OR ipsilateral supraclavicular nodes

M — Distant Metastasis

M0: No distant metastasis
M1: Distant metastasis (bone, liver, lung, brain, contralateral nodal)

Overall Stage Groups

Stage	TNM	5-Year Survival
0	Tis N0 M0	~99%
I	T1 N0 M0	~95–99%
IIA	T0-1 N1 M0 / T2 N0 M0	~85–90%
IIB	T2 N1 M0 / T3 N0 M0	~75–85%
IIIA	T0-3 N2 M0 / T3 N1 M0	~50–70%
IIIB	T4 N0-2 M0	~40–50%
IIIC	Any T N3 M0	~30–40%
IV	Any T Any N M1	~28% (5yr)

— Mulholland & Greenfield's Surgery; Sabiston Textbook of Surgery; Harrison's 22E

12. MANAGEMENT OVERVIEW

A. Multidisciplinary Team (MDT)

Management requires coordination between: surgeon, medical oncologist, radiation oncologist, radiologist, pathologist, breast care nurse, geneticist, reconstructive surgeon, and palliative care.

B. Surgery

Procedure	Indication
Breast-conserving surgery (BCS / Lumpectomy)	Stages I–II; followed by radiotherapy; equivalent survival to mastectomy
Modified Radical Mastectomy (MRM)	Multifocal disease, prior RT, large tumour, patient preference
Sentinel Lymph Node Biopsy (SLNB)	Clinically node-negative; radioactive tracer ± blue dye
Axillary Lymph Node Dissection (ALND)	Palpable nodes or extensively involved sentinel nodes
Nipple-sparing / Skin-sparing Mastectomy	Reconstruction options; prophylactic mastectomy for BRCA+
Reconstruction	Implant or autologous tissue (TRAM, DIEP flap) — immediate or delayed

Evidence: Six major RCTs (including NSABP B-06, Milan I) demonstrated equivalent overall survival between BCT + RT and mastectomy for stages I–II.

C. Radiotherapy

After BCS: Whole-breast radiotherapy reduces recurrence from ~40% to <10%
Post-mastectomy RT: For ≥4 positive nodes, T3/T4 tumors, or positive margins
Can be given in accelerated/hypofractionated schedules

D. Systemic Therapy

Endocrine Therapy (ER/PR positive)

Drug	Menopausal Status
Tamoxifen (SERM, 20 mg/day × 5–10 yrs)	Any; standard for premenopausal
Aromatase inhibitors (anastrozole, letrozole, exemestane)	Postmenopausal only; superior to tamoxifen
GnRH agonists (goserelin, leuprolide)	Premenopausal; induces ovarian suppression to postmenopausal levels
CDK 4/6 inhibitors (abemaciclib, ribociclib)	High-risk early ER+ combined with endocrine therapy

Chemotherapy (for HER2+, TNBC, high-risk ER+)

Regimens: AC-T (doxorubicin + cyclophosphamide → paclitaxel/docetaxel)
Also: 5-FU, methotrexate, carboplatin/cisplatin (TNBC/BRCA)
Neoadjuvant chemotherapy: For locally advanced, IBC, or large tumors to downstage before surgery

Anti-HER2 Therapy (HER2+)

Trastuzumab + Pertuzumab (monoclonal antibodies): 1 year adjuvant
Neratinib, Lapatinib (tyrosine kinase inhibitors): For HER2+ early breast cancer
T-DM1 (ado-trastuzumab emtansine): For residual HER2+ disease after neoadjuvant therapy

PARP Inhibitors (BRCA-mutated, HER2-negative)

Olaparib: Adjuvant for high-risk germline BRCA-mutated, HER2-negative tumors after chemotherapy

Immunotherapy

Pembrolizumab (PD-1 inhibitor): FDA-approved for TNBC in neoadjuvant + adjuvant setting

E. Metastatic (Stage IV) Breast Cancer

Goal: Palliation, symptom control, prolongation of survival
Sequential systemic therapy based on receptor status
Bone metastases: Bisphosphonates (zoledronic acid), denosumab; radiotherapy for pain
Brain metastases: Whole-brain RT, stereotactic radiosurgery, lapatinib + capecitabine
Median survival for metastatic BC: 2–3 years (improving with modern targeted agents)

F. Prevention & Chemoprevention

Tamoxifen (20 mg/day × 5 yrs): 49% reduction in ER+ invasive breast cancer in high-risk women
Raloxifene: Similar efficacy with fewer uterine side effects
Aromatase inhibitors (anastrozole, exemestane): Highly effective for postmenopausal high-risk women
BRCA carriers: Risk-reducing bilateral salpingo-oophorectomy (PBSO) — proven mortality benefit; bilateral prophylactic mastectomy (BPM) — reduces incidence but less clear mortality benefit

— Goldman-Cecil Medicine; Harrison's 22E, p. 2082–2090; Sabiston; Mulholland & Greenfield

13. PROGNOSIS & PROGNOSTIC FACTORS

Favorable Prognostic Factors:

Small tumor size (T1)
Node-negative (N0)
Low grade (Grade 1)
ER/PR positive
HER2 negative
Low Ki-67
No lymphovascular invasion
Luminal A subtype

Unfavorable Prognostic Factors:

Large tumor, extensive nodal involvement
High grade (Grade 3)
Triple negative (TNBC)
HER2-enriched
Lymphovascular invasion
High Ki-67
Young age (<35 years)
Metastatic disease

Genomic Tests (for ER+ HER2− early disease):

Oncotype DX (21-gene recurrence score): Guides chemotherapy decision in node-negative/low nodal burden ER+ disease
MammaPrint (70-gene): Identifies low/high genomic risk
Prosigna PAM50: Intrinsic subtype and ROR score

14. DIFFERENTIAL DIAGNOSIS

When a patient presents with a breast lump or symptoms:

Diagnosis	Distinguishing Features
Fibroadenoma	Young women, rubbery, mobile, well-defined, non-tender
Fibrocystic change	Cyclic pain, bilateral nodularity, premenopausal
Simple cyst	Well-defined, smooth, transilluminates, confirmed on US
Lipoma	Soft, mobile, compressible
Mastitis / Breast abscess	Lactating women, hot, erythematous, tender, fever; responds to antibiotics
Inflammatory breast cancer	Mimics mastitis but does NOT respond to antibiotics; no puerperal state; skin biopsy confirms
Duct ectasia	Multiparous, thick white nipple discharge, periareolar mass
Fat necrosis	History of trauma/surgery; spiculated on mammogram — must biopsy to exclude cancer
Paget disease	Unilateral nipple eczema — biopsy to exclude Paget disease of nipple
Phyllodes tumor	Rapidly growing, large, lobulated; can be benign or malignant

15. SAMPLE HoPI TEMPLATE (For Presenting a Breast Cancer Case at Seminar)

"Mrs. X, a [age]-year-old [menopausal status] female, presented with a [duration]-week history of a painless/painful lump in the [right/left] breast. The lump was first noticed [when/how — incidentally vs. self-exam vs. mammogram]. It is located in the [upper outer/inner/lower] quadrant, is approximately [size] cm by palpation, hard in consistency, with irregular margins, and appears fixed to the underlying tissue. She also reports [skin dimpling / nipple retraction / nipple discharge — character / axillary lump / none]. She denies [contralateral breast symptoms, skin ulceration, peau d'orange]. There are no features to suggest metastatic disease including no bone pain, dyspnoea, cough, or neurological symptoms. Her weight has [been stable / decreased by X kg over X months].

Regarding risk factors: She attained menarche at age [X], has [G_P_] parity with her first pregnancy at age [X], [breast-fed / did not breast-feed]. Menopause occurred at age [X]. She [has / has not] used HRT. She has [no / positive] family history of breast or ovarian cancer — specifically [describe family members and ages]. She underwent [no / bilateral prophylactic] prior breast surgery. She has no prior chest wall radiation.

She takes [medications] and has [no / the following] known allergies."

Sources:

Goldman-Cecil Medicine International Edition, Chapter 183 (Breast Cancer)
Harrison's Principles of Internal Medicine, 22E, Chapter 84
Sabiston Textbook of Surgery, Chapter 68 (Diseases of the Breast)
Robbins & Cotran Pathologic Basis of Disease, Chapter 23
Mulholland & Greenfield's Surgery, Chapter 74
AJCC Cancer Staging Manual, 8th Edition

---Here is a complete, seminar-ready presentation of Breast Cancer — History of Presenting Illness (HoPI) synthesized from Goldman-Cecil Medicine, Harrison's 22E, Sabiston Surgery, Robbins Pathology, and Mulholland & Greenfield's Surgery.

🎓 BREAST CANCER — DETAILED HoPI FOR SEMINAR

1. EPIDEMIOLOGY

Most common non-skin malignancy in women worldwide — ~2.25 million new cases/year globally; ~290,000/year in the U.S.; ~43,000 deaths/year
Lifetime cumulative incidence: 12.9% in women
75% of cases occur in women >50 years old
Males represent <1% of cases but present at more advanced stages
Incidence declining due to reduced HRT use, mammographic screening, and adjuvant therapies

2. RISK FACTORS (Box 68.1 — Sabiston)

Demographic & Lifestyle

Factor	Detail
Age	#1 risk factor; rare <20 yrs; peaks in 8th decade
Female sex	Predominantly female
Obesity	Postmenopausal; peripheral aromatization → estrogen
Alcohol	Dose-dependent
Physical inactivity, smoking	Modifiable
Shift (nighttime) work	Established risk

Hormonal Exposure

Early menarche (<11 yrs), late menopause (>55 yrs) → prolonged estrogen exposure
Nulliparity, first pregnancy after age 30, lack of breastfeeding
Combined E+P HRT significantly increases risk; estrogen-only does NOT
Ongoing oral contraceptive use

Genetic / Family History

~20% have family history; first-degree relative with premenopausal BC = significant risk
BRCA1/BRCA2 mutations → 50–85% lifetime risk; autosomal dominant
TP53 (Li-Fraumeni), PTEN (Cowden), PALB2, CHEK2, ATM
5–8% of breast cancers are hereditary; Ashkenazi Jewish background = higher BRCA1/2 prevalence

Histologic Risk Factors

Lesion	Relative Risk
Proliferative disease without atypia	1.3–1.9×
Atypical ductal/lobular hyperplasia	3.7–4.2×
LCIS	>7×

Environmental

Chest wall ionizing radiation in adolescence (e.g., Hodgkin lymphoma treatment)

3. PATHOLOGY

In Situ Lesions

Feature	LCIS	DCIS
Palpable mass	No	Uncommon
Mammogram	Not visible	Microcalcifications
E-cadherin	Negative	Positive
Cancer risk	25% in either breast (lifetime)	0.5%/yr at same site

Invasive Types

IDC/NST (~75%) — most common; haphazard glandular invasion
ILC — "Indian-file" single-cell pattern; E-cadherin negative
Tubular — well-differentiated; best prognosis
Mucinous/Colloid — tumor cells in mucin lakes; good prognosis
Medullary — undifferentiated, lymphocytic infiltrate; BRCA1-associated
Paget disease — DCIS extending into nipple skin; eczematous nipple

Molecular Subtypes

Subtype	ER	PR	HER2	%
Luminal A	+	+	−	40–60%
Luminal B	+	+/−	−/+	20–30%
HER2-enriched	−	−	+	10–20%
Triple negative (TNBC)	−	−	−	10–20%

4. CLINICAL PRESENTATION — HoPI CORE

Presenting Complaint

The classical presentation is a painless, hard, irregular, fixed breast lump, usually self-detected or found on screening mammography.

Systematic HoPI Questions

🔵 The Lump

Site: Which breast? Which quadrant? (Most common: upper outer quadrant, ~50%)
Onset & Duration: When noticed? How?
Character: Hard vs. soft; irregular vs. smooth; mobile vs. fixed to skin or deep tissue
Size: Estimated size; has it changed?
Malignant features: Hard, irregular, non-tender, fixed, with ill-defined margins

🔵 Skin Changes

Dimpling / tethering: Cooper's ligament involvement
Peau d'orange (orange-peel skin): Lymphatic blockage; hallmark of Inflammatory Breast Cancer (IBC)
Skin ulceration / satellite nodules: T4b disease
Erythema, warmth: IBC — must distinguish from mastitis (no response to antibiotics)
Nipple retraction: Tumor traction or periductal fibrosis

🔵 Nipple Discharge

Bloody / serosanguineous → most suspicious for malignancy
Milky → galactorrhoea (prolactinoma)
Green/yellow → duct ectasia
Unilateral > bilateral (more concerning)

🔵 Nipple Changes

Paget's disease: Unilateral eczematous, scaly, crusted nipple ± palpable mass; biopsy mandatory

🔵 Pain

Breast cancer is typically painless in early stages — pain is more a feature of benign disease
Ask about bone pain (back, hips, ribs) → bone metastases (most common metastatic site)

🔵 Axillary / Nodal Disease

Palpable axillary lumps: Mobile or fixed? Matted? Number?
Arm swelling (lymphoedema) or arm pain
Supraclavicular nodes → N3 disease (stage IIIC)

🔵 Metastatic Symptoms (Systems Review)

Site	Symptoms
Bone	Back/hip/rib pain, pathological fracture, hypercalcaemia
Lung	Dyspnoea, cough, haemoptysis, pleural effusion
Liver	RUQ pain, jaundice, nausea, weight loss
Brain	Headache, seizures, focal neurological deficits
Skin	Cutaneous nodules

🔵 Constitutional Symptoms

Unintentional weight loss, fatigue, anorexia, night sweats

5. PAST HISTORY

Prior breast lumps, biopsies, atypical hyperplasia, LCIS
Previous breast cancer (ipsilateral or contralateral)
Prior chest wall radiation

6. GYNAECOLOGICAL HISTORY

Age at menarche, parity, age at first delivery, breastfeeding
Menopausal status and age at menopause
HRT use (type: combined vs. estrogen-only; duration)
Oral contraceptive use

7. FAMILY HISTORY

Breast cancer in 1st-degree relatives — age at diagnosis
Ovarian cancer (BRCA1/2 syndrome)
Bilateral breast cancer in relatives
Male relatives with breast cancer (BRCA2)
Li-Fraumeni features (sarcomas, adrenal tumors in young relatives)

8. SOCIAL HISTORY

Alcohol, smoking, obesity, physical activity
Occupation (night shift)
Psychological impact, support system

9. DRUG HISTORY

HRT, OCPs, tamoxifen, aromatase inhibitors
Prior chemotherapy
Allergies (particularly contrast/iodine)

10. INVESTIGATIONS

Triple Assessment

Clinical examination (history + physical)
Radiological: Mammogram ± Ultrasound ± MRI
Pathological: Core Needle Biopsy (CNB) — preferred over FNAC

Imaging	Purpose
Mammography	Screening + diagnosis; microcalcifications, masses; ↓ mortality 20–25% in ≥50 yrs
Ultrasound	Palpable mass, cyst vs. solid, node assessment, biopsy guidance
Breast MRI	BRCA carriers, dense breasts, extent of disease, neoadjuvant response
CT CAP	Staging metastatic/locally advanced disease
Bone scan	Bone metastases (with elevated ALP, bone pain)
PET-CT	Selected high-risk staging

Biomarkers (on CNB)

Marker	Purpose
ER/PR	Endocrine therapy eligibility
HER2	Anti-HER2 therapy
Ki-67	Luminal A vs B distinction
BRCA1/2	Germline testing in selected patients

Bloods

FBC, LFTs, serum calcium, ALP, tumour markers (CA 15-3, CEA)

11. STAGING — AJCC 8th Edition TNM

T (Tumour)

Tis: DCIS | T1: ≤20 mm | T2: 20–50 mm | T3: >50 mm | T4d: Inflammatory BC

N (Nodes — Pathologic)

pN0: None | pN1: 1–3 axillary nodes | pN2: 4–9 nodes | pN3: ≥10 nodes / supraclavicular

Stage Groups

Stage	Approx. 5-yr Survival
0 (Tis)	~99%
I	~95%
II	~75–90%
III	~40–70%
IV	~28%

12. MANAGEMENT OVERVIEW

Surgery

BCS + Radiotherapy = equivalent survival to mastectomy (Stages I–II); proven in NSABP B-06, Milan I trial
SLNB: For clinically node-negative patients
ALND: For palpable or extensively involved nodes
Mastectomy: Multifocal, large tumor, prior RT, patient preference; reconstruction offered

Radiotherapy

Post-BCS: Reduces local recurrence from ~40% → <10%
Post-mastectomy: For ≥4 positive nodes, T3/T4, positive margins

Systemic Therapy

Target	Agent(s)
ER+	Tamoxifen (pre-/perimenopausal) / AIs (postmenopausal) / GnRH agonists; CDK4/6 inhibitors for high-risk
HER2+	Trastuzumab + pertuzumab; neratinib; T-DM1 for residual disease
TNBC	Chemotherapy (AC-T); pembrolizumab (FDA-approved)
BRCA-mutated	Olaparib (PARP inhibitor) post-chemotherapy

13. DIFFERENTIAL DIAGNOSIS

Fibroadenoma (young, mobile, non-tender)
Simple cyst (smooth, transilluminates)
Fibrocystic change (cyclic pain, bilateral)
Mastitis / breast abscess (lactating, febrile, responds to antibiotics)
Inflammatory BC (mimics mastitis but antibiotic-resistant)
Duct ectasia, fat necrosis, phyllodes tumor

14. SAMPLE CASE HoPI TEMPLATE

"Mrs. [X], a [age]-year-old [pre/post]menopausal female, presented with a [duration] history of a painless, hard, irregular lump in the [right/left] [upper outer/other] quadrant of the breast, first noticed on [self-examination / mammogram / incidentally]. The lump is approximately [size] cm, hard in consistency, with ill-defined irregular margins, and appears fixed to the underlying tissue. She also reports [nipple retraction / skin dimpling / axillary swelling / nipple discharge — describe]. She denies features of metastatic disease including bone pain, dyspnoea, jaundice, or neurological symptoms. She has [no / significant] weight loss.

Risk factors: menarche at age [X], G[]P[], first delivery at age [X], [breastfed/not]. Menopause at [age]. She [has/has not] used combined HRT for [duration]. Family history: [details — mother/sister with BC; BRCA status if known]."

Key Textbook Sources:

Goldman-Cecil Medicine, Chapter 183 — Breast Cancer
Harrison's Principles of Internal Medicine 22E, Chapter 84
Sabiston Textbook of Surgery, Chapter 68
Robbins & Cotran Pathologic Basis of Disease, Chapter 23
Mulholland & Greenfield's Surgery, Chapter 74
AJCC Cancer Staging Manual, 8th Edition (2017)

This is a shared conversation. Sign in to Orris to start your own chat.